Highline Therapeutics Announces Alliance With Weill Cornell Medical College to Accelerate Biotech Company Formation

NEW YORK--()--Highline Therapeutics, a Versant Ventures biotech incubator, today announced an agreement with Weill Cornell Medical College to partner on translational research programs. Highline will fund and incubate selected programs, proposed by Weill Cornell, with the aim of establishing Versant-backed spinout companies within the term of the agreement. The first of these collaborative programs have been identified within the focus areas of oncology and immunology.

"We are pleased to enter into this agreement with Highline, under which we will be delivering on our mission to bring new therapies to patients and helping to foster a biotech ecosystem in New York City," said Larry Schlossman, Managing Director of Biopharma Alliances and Research Collaborations at Weill Cornell. "Highline and Versant bring deep company-building expertise to the partnership, which will substantially increase the probability of success."

"We are delighted to partner with Weill Cornell, one of the premier medical research institutions in New York City. Together, we aim to bridge the gap between academic research and the technology development required to enable biotech company formation," said Carlo Rizzuto, Versant Venture Partner and CEO, Highline Therapeutics.

About Highline Therapeutics

Highline Therapeutics is a biotech incubator established by Versant Ventures in New York City. Modeled on Blueline Bioscience in Toronto, Highline aims to identify and accelerate translational research and biotech company formation. Highline will partner with both local academic institutions and pharmaceutical companies to help bridge the gap between academic science and the development of novel therapeutics.

 

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.